BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Immune Response BioPharma Plans Listing on German Exchanges to Fund Blockbuster Drug NeuroVax


6/4/2012 9:46:25 AM

PRLog (Press Release) - Jun 03, 2012 - Immune Response BioPharma, Inc. Plans Listing on German Exchanges to Fund Blockbuster MS Drug NeuroVax which is a first in class and best in class Multiple Sclerosis Vaccine.

IRBP has decided to pursue a listing on the German Exchanges, we will first list on the Berlin Exchange and then move to the Frankfurt Exchange. NeuroVax is the first MS Vaccine is a first in class and best in class drug that restores deficient FOXP3+ T-Regs which is the key to halting the disease and repairing the damaged T-Cells. NeuroVax has the potential to become treatment of choice for MS patients and do annual sales of north of a billion dollars.

"IRBP will determine the timing, pricing and sale of any shares to be listed on the German Exchanges. Raising sufficient capital and giving investors a liquid investment vehicle will enhance our ability to raise the necessary funds to drive NeuroVax to regulatory and eventual FDA approval. We will continue to seek a corporate partnership for NeuroVax, although we may choose to fund the development costs and own the drug and become the new power in Pharma" IRBP CEO Mr. David Buswell

Immune Response BioPharma, Inc. maybe found on the WorldWide Web @ www.immuneresponsebiopharma.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->